P/E ratio for Oramed Pharmaceuticals (ORMP)

P/E ratio history for Oramed Pharmaceuticals from 2007 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Ultragenyx RARE	-5.32	9.31%	🇺🇸 USA
Novo Nordisk NVO	42.3	-969.60%	🇩🇰 Denmark
Sanofi SNY	18.1	-472.78%	🇫🇷 France
Compugen CGEN	-4.51	-7.20%	🇮🇱 Israel
Lexicon Pharmaceuticals LXRX	-2.35	-51.61%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.